Rheumatoid arthritis
Conditions
Interventions
Test group:Biological preparations/targeted drugs + tryptophan dietary supplements
Control group:Biological preparations/targeted drugs
Sponsors
Dazhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. All met the revised RA diagnostic criteria of the American College of Rheumatology in 2010. 2. RA patients aged 18 to 80 years old. 3. Disease activity score (DAS28) >= 3.0. 4. Patients with poor response to conventional disease-modifying antirheumatic drugs. 5. Patients who had received biological agents/targeted drugs (including adalimumab, tocilizumab, tofacitinib, etc.) before enrollment. 6. Patients with good compliance, who signed the informed consent form and were able to complete the trial according to the protocol.
Exclusion criteria
Exclusion criteria: 1. Patients with peptic ulcers, hematological disorders, mental disorders, infectious diseases, and malignant tumors. 2. Those with a history of inflammatory joint diseases other than rheumatoid arthritis in their past or current medical history, or those with concurrent systemic autoimmune diseases. 3. Patients with a recent history of major surgery or trauma. 4. Those with severe, poorly controlled comorbidities that the investigator deems clinically significant. 5. Patients with poor compliance who cannot cooperate to complete the trial. 6. Patients with a history of depression and currently taking related medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease activity score (DAS28);Swollen joint count (SJC28);Tender joint counts (TJC28);Erythrocyte sedimentation rate (ESR);C-reactive protein (CRP);Rheumatoid factor (RF); | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scal Score;Health Assessment Questionnaire for the Disability Index; | — |
Countries
China
Contacts
Public ContactFanxin Zeng
Dazhou Central Hospital
Outcome results
None listed